CNS diseases are a huge unmet medical need in our society. Why? Because CNS drug discovery is notoriously difficult. But for the companies that get it right and produce new successful therapeutics, the rewards, both commercially and socially will be huge. So what can be done to ensure more CNS drugs make it to market?
The problems drug developers face tend to be very similar across the industry. Unreliable animal models. Validating new biomarkers. Detecting if a drug has reached the brain. However the solutions to tackle these problems are different across the board. There is a real hunger for a consolidation of ideas to decide what is best practice.
Translational CNS is first and foremost a summit, a meeting of leading minds in the CNS field. Where the key issues can be discussed, where progress can be made, where people can decide how to mitigate risk of failure.
The agenda has been designed by experts from Eli Lilly, Takeda, Eisai, and more. It will cover how to avoid the pitfalls that cause CNS drugs to fail and enable you to increase the clinical success rate of your CNS drugs